Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody
Tóm tắt
Recombinant humanized antivascular endothelial growth factor (rhuMAbVEGF) is a monoclonal IgG, antibody that is being developed as an antiangiogenic agent for use in treating a variety of solid tumors. Preclinical safety studies included an immunohistochemical tissue cross-reactivity study, in vitro hemolytic potential and blood compatibility studies, and multiple dose toxicity studies. Toxicity studies were conducted in cynomolgus monkey because rhuMAbVEGF is pharmacologically active in this species and does not bind rat or mouse vascular endothelial growth factor (VEGF). Following twice weekly administration of rhuMAbVEGF for 4 or 13 wk, young adult cynomolgus monkeys exhibited physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes, subchondral bony plate formation, and inhibition of vascular invasion of the growth plate. In addition, decreased ovarian and uterine weights and an absence of corpora lutea were observed in females receiving 10 and 50 mg/kg/dose in the 13-wk study. Both the physeal and ovarian changes were reversible with cessation of treatment. No other treatment-related effects were observed following rhuMAbVEGF administration at doses up to 50 mg/kg. These findings indicate that VEGF is required for longitudinal bone growth and corpora lutea formation and that rhuMAbVEGF can reversibly inhibit physiologic neovascularization at these sites.
Từ khóa
Tài liệu tham khảo
Borgström P., 1996, Cancer Res., 56, 4032
Brown LF, 1993, Am. J. Pathol., 143, 1255
Brown LF, 1993, Cancer Res., 53, 4727
Center for Biologics Evaluation and Research, Food and Drug Administration, 1997, Points to consider in the manufacture and testing of monoclonal antibody products for human use. CBER
Dvorak HF, 1995, Am. J. Pathol., 146, 1029
Fava RA, 1994, J. Exp. Med., 180, 340
Garner A. (1994). Vascular diseases. In: Pathobiology of Ocular Diseases. A Dynamic Approach, A Garner and GK Klintworth, (eds). Marcel Dekker, New York, pp. 1625-1710.
Iannotti JP (1990). Growth plate physiology and pathology. In: Pathologic Fractures in Metabolic Bone Disease, The Orthopedic Clinics of North America, Philadelphia, pp. 1-17.
Kamat BR, 1995, Am. J. Pathol., 146, 157
Lopez PF, 1996, Invest. Ophthalmol. Vis. Sci., 37, 855
Melnyk O., 1996, Cancer Res., 56, 921
Minchenko A., 1994, Lab. Invest., 71, 374
Presta LG, 1997, Cancer Res., 57, 4593
Schroff RW, 1985, Cancer Res., 45, 879
Shima DT, 1996, Invest. Ophthalmol. Vis. Sci., 37, 1334